HOME >> BIOLOGY >> NEWS
Cancer risk clouds gene cures

DESPITE its spectacular achievements, the first successful form of gene therapy will for now be used only as a last resort due to the risk of cancer. And that's not the only bad news. The latest studies suggest that some other gene therapies using different viruses might also trigger cancer.

The Necker Hospital in Paris pioneered the use of gene therapy to cure the severe inherited immune disease called X-SCID. But two of the 11 boys treated have developed leukaemia. Both these cases appear to be due to the corrective gene being inserted near another gene called Lmo2, which helps control cell growth and can contribute to cancer if turned on at the wrong time (New Scientist, 25 January, p 12).

Calculations by Christof von Kalle of the University of Cincinnati College of Medicine in Ohio suggest that rather than being an extraordinary coincidence the engineered mouse retrovirus used to deliver the gene in the French studymay insert it near Lmo2 about once per 100,000 insertions. Since millions of bone marrow cells are modified and returned to the boys, such insertions may crop up in most if not all of the patients.

The added gene has now turned up near Lmo2 in a third child in the French trial, von Kalle last week told a gene therapy conference in Banff, Canada. Fortunately, the boy shows no signs of leukaemia, suggesting that a further genetic defect may be necessary to trigger uncontrolled growth of the modified cells.

Gene therapists are still hoping that this problem will prove specific to the gene or methods used in the X-SCID therapy. But experiments done by Frederic Bushman of the Salk Institute near San Diego suggests there could also be a potential problem with HIV and other related retroviruses, which many researchers are planning to use in gene therapy.

Bushman infected human cells with the viruses and looked to see where they landed. Last year, he reported that the viruses are more likely to land in genes- especially in active on
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
12-Mar-2003


Page: 1 2

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 01, 2016 ... ... the US Computational Science Symposium (CSS) and the popularity of US Single Day ... will take place in early Summer 2018, in Raleigh, NC. Topics of the ...
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)... 30, 2016 /PRNewswire/ -  Equicare Health Inc ., the ... recognized as one of the top 100 companies in ... listing that distinguishes the top digital health companies across ... step forward this year continually upgrading our product with ... base and team," says Len Grenier , CEO ...
Breaking Biology Technology:
Cached News: